BiomX Analyst Ratings
BiomX Buy Rating Affirmed by Analyst Michael Higgins on Strong Clinical Progress and Strategic Acquisitions
BiomX Analyst Ratings
BiomX Buy Rating Affirmed on Clinical Progress and Strategic Acquisition
BiomX Analyst Ratings
BiomX's Strategic Progress and Positive Trials Fuel Buy Rating
BiomX Analyst Ratings
Biomx Inc. at a Crossroads: Shareholder Approval Required for Convertible Securities Amid Liquidity Concerns
Analysts Are Bullish on These Healthcare Stocks: BiomX (PHGE), Daré Bioscience (DARE)
BiomX Analyst Ratings
BiomX's Robust Financial Health and Promising Clinical Advancements Bolster Buy Rating
BiomX Analyst Ratings
BiomX Buy Rating Justified by Merger Synergy, Enhanced Financial Stability, and Promising Clinical Trials
Analysts' Opinions Are Mixed on These Healthcare Stocks: CytomX Therapeutics (CTMX), BiomX (PHGE) and Moderna (MRNA)
Buy Rating Affirmed for BiomX as BX004 Shows Strong Efficacy in Phase 2a Cystic Fibrosis Study
Promising Clinical Trials and Financial Stability Bolster BiomX's Buy Rating: An Analysis by Michael Higgins
HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $7 Price Target
BiomX Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BiomX (PHGE), Quoin Pharmaceuticals (QNRX) and Precigen (PGEN)
BiomX's BX004: Promising Phase 1b/2a Study Results and High Market Expectations Lead to Buy Rating
No Data
No Data